Jemperli (Dostarlimab) Market Report 2026

Jemperli (Dostarlimab) Market Overview

• The Jemperli (Dostarlimab) market growth in the historic period has been driven by advances in immune checkpoint inhibitors, rising cancer prevalence • Market expansion is supported by expansion into additional cancer indications, increasing use of combination therapies • Growth Driver: Increasing Cancer Incidence Driving Growth Of Market Expansion • Market Trend: Recent Developments And Efficacy Of Jemperli (Dostarlimab) In Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Jemperli (Dostarlimab) Market?

Jemperli (dostarlimab) is a monoclonal antibody used in cancer immunotherapy. It works as a PD-1 inhibitor, blocking the interaction between PD-1 and its ligands, thereby enhancing the immune system's ability to fight cancer. It is primarily approved for treating certain types of endometrial and non-small cell lung cancer. The main patient demographics of jemperli (dostarlimab) are adult patients, elderly patients, and high-risk groups. Adult patients are individuals aged 18 years or older. Jemperli (dostarlimab) treats adult patients with specific types of advanced or recurrent cancers, particularly endometrial or mismatch repair-deficient tumors, by enhancing the immune system's ability to attack cancer cells. It has applications in cancer treatment and combination therapy and distributed through hospitals, specialty clinics, pharmacies, and online pharmacies.

What Is The Jemperli (Dostarlimab) Market Growth Forecast?

The growth in the forecast period can be attributed to expansion into additional cancer indications, increasing use of combination therapies, growing biomarker testing adoption, rising oncology healthcare spending, improved survival outcomes. Major trends in the forecast period include expansion of pd-1 inhibitor therapies, growth in cancer immunotherapy adoption, personalized oncology treatment strategies, combination immunotherapy regimens, biomarker-driven cancer care.

Global Jemperli (Dostarlimab) Market Segmentation

1) By Patient Demographics: Adult Patients, Elderly Patients, High-Risk Groups 2) By Application: Cancer Treatment, Combination Therapy 3) By Distribution Channel: Hospitals, Specialty Clinics, Pharmacies, Online Pharmacies

What Are The Drivers Of The Jemperli (Dostarlimab) Market?

The increasing cancer incidence is expected to propel the growth of the jemperli (dostarlimab) market going forward. Rising cancer cases are due to factors such as poor nutrition, smoking, obesity, environmental pollution, and increased screening, alongside an aging population and lifestyle changes among younger individuals. Jemperli (dostarlimab) is used to treat advanced or recurrent endometrial cancer, particularly in patients with mismatch repair deficiency, enhancing the immune response against cancer cells when combined with chemotherapy. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia's health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Additionally, in 2024, cancer is anticipated to account for about 3 out of every 10 deaths in the country. Therefore, the increasing cancer incidence is driving the growth of the jemperli (dostarlimab) industry. The growing demand for personalized medicine is expected to drive the growth of the jemperli (dostarlimab) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, needs, and genetic profile of each patient. The growing demand for personalized medicine is driven by advancements in genomics, targeted therapies, and the increasing prevalence of chronic diseases that require more precise treatment approaches. Personalized medicine leverages Jemperli (dostarlimab) by targeting specific genetic mutations in tumors, such as mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) cancers, to enhance treatment effectiveness. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the jemperli (dostarlimab) industry.

Key Players In The Global Jemperli (Dostarlimab) Market

Major companies operating in the jemperli (dostarlimab) market are GlaxoSmithKline (GSK) Plc

Global Jemperli (Dostarlimab) Market Trends and Insights

The key trend in the jemperli (dostarlimab) market is centered on innovations to achieve progress in cancer treatment, such as chemotherapy. Chemotherapy, a cancer treatment, uses powerful drugs to destroy rapidly growing cells, primarily targeting cancer cells. It can serve as a curative or palliative approach and is often combined with other therapies to improve effectiveness and manage symptoms. For instance, in July 2023, GlaxoSmithKline (GSK) plc, a UK-based biopharma company, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for jemperli (dostarlimab), seeking to expand its use in combination with chemotherapy for treating adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

Regional Insights

North America was the largest region in the jemperli (dostarlimab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Jemperli (Dostarlimab) Market?

The jemperli (dostarlimab) market consists of sales of jemperli (dostarlimab-gxly) injection and jemperli plus chemotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Jemperli (Dostarlimab) Market Report 2026?

The jemperli (dostarlimab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the jemperli (dostarlimab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.